Mergers & acquisitions
Invitae Corporation, a leading medical genetics company, has announced that it has entered into a definitive agreement to acquire Jungla Inc.
Acquired assets from NCARDIA AG include IP portfolio, IPSC-based cellular products and an experienced stem cell biology team
The M&A moves are expected to increase the oncology pipelines of both companies.
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH
Roche and Spark initially agreed to the acquisition in February of this year. The deal has had mutiple delays due to regulatory scrutiny.
Evotec SE announced that the strategic transaction to acquire Just Biotherapeutics, signed on 20 May 2019, has been completed.
Chignolo D’Isola, Bergamo, Italy – July 1, 2019 – Flamma SpA, a preeminent Contract Development and Manufacturing Organization that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients for the pharmaceutical industry, is proud to announce that the company has acquired the Teva’s Chemical Synthesis Center in Malvern, PA in the Philadelphia area.
Novartis announced that it has completed its acquisition of Xiidra® 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.
Financial details of the deal were not disclosed, but Lonza said it plans to retain the Novartis employees currently working at the facility.
PRESS RELEASES